Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

2 results

Results by year

Filters applied: . Clear all
Page 1
Immune Checkpoint Inhibitor-Related Myocarditis: Recognition, Surveillance, and Management.
Kuhnly NM, Coviello J. Kuhnly NM, et al. Clin J Oncol Nurs. 2022 Feb 1;26(1):54-60. doi: 10.1188/22.CJON.54-60. Clin J Oncol Nurs. 2022. PMID: 35073300 Review.
BACKGROUND: Immune checkpoint inhibitor (ICI) therapy is an effective treatment for many patients. Although rare, immune-mediated cardiovascular adverse events can occur, including myocarditis. ...
BACKGROUND: Immune checkpoint inhibitor (ICI) therapy is an effective treatment for many patients. Although rare …
Role of Biomarkers in the Management of Immune-Checkpoint Inhibitor-Related Myocarditis.
Vasbinder A, Ismail A, Salem JE, Hayek SS. Vasbinder A, et al. Curr Cardiol Rep. 2023 Sep;25(9):959-967. doi: 10.1007/s11886-023-01915-5. Epub 2023 Jul 12. Curr Cardiol Rep. 2023. PMID: 37436648 Review.
PURPOSE OF REVIEW: Immune checkpoint inhibitor (ICI)-related myocarditis poses a major clinical challenge given its non-specific presentation, rapid progression, and high mortality rate. Here, we review the role of blood-based biomarkers in the …
PURPOSE OF REVIEW: Immune checkpoint inhibitor (ICI)-related myocarditis poses a major clinical challenge …